Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice

Kelly A. Martin, Nicholas R. Hum, Aimy Sebastian, Wei He, Salma Siddiqui, Paramita M. Ghosh, Chong Xian Pan, Ralph de Vere White, Gabriela G. Loots

Research output: Contribution to journalArticle

Abstract

Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer. We have utilized a patient-derived bladder cancer xenograft (PDX) platform to characterize molecular mechanisms that contribute to relapse following drug treatment in advanced bladder cancer. Transcriptomic profiling of bladder cancer xenograft tumors by RNA-sequencing analysis, before and after relapse, following a 21-day cisplatin/gemcitabine drug treatment regimen identified methionine adenosyltransferase 1a (MAT1A) as one of the significantly upregulated genes following drug treatment. Survey of patient tumor sections confirmed elevated levels of MAT1A in individuals who received chemotherapy. Overexpression of MAT1A in 5637 bladder cancer cells increased tolerance to gemcitabine and stalled cell proliferation rates, suggesting MAT1A upregulation as a potential mechanism by which bladder cancer cells persist in a quiescent state to evade chemotherapy.

Original languageEnglish (US)
JournalInternational journal of molecular sciences
Volume20
Issue number20
DOIs
StatePublished - Oct 9 2019

Fingerprint

Methionine Adenosyltransferase
Drug therapy
methionine
Chemotherapy
bladder
chemotherapy
gemcitabine
Drug Resistance
Urinary Bladder Neoplasms
mice
Tumors
Cell Survival
drugs
cancer
Cells
Drug Therapy
Heterografts
Pharmaceutical Preparations
Cell proliferation
Neoplasms

Keywords

  • bladder cancer
  • drug resistance
  • gemcitabine
  • methyltransferase

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. / Martin, Kelly A.; Hum, Nicholas R.; Sebastian, Aimy; He, Wei; Siddiqui, Salma; Ghosh, Paramita M.; Pan, Chong Xian; de Vere White, Ralph; Loots, Gabriela G.

In: International journal of molecular sciences, Vol. 20, No. 20, 09.10.2019.

Research output: Contribution to journalArticle

@article{58a8de68fab9418ba0ed2d8742e7c9a0,
title = "Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice",
abstract = "Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer. We have utilized a patient-derived bladder cancer xenograft (PDX) platform to characterize molecular mechanisms that contribute to relapse following drug treatment in advanced bladder cancer. Transcriptomic profiling of bladder cancer xenograft tumors by RNA-sequencing analysis, before and after relapse, following a 21-day cisplatin/gemcitabine drug treatment regimen identified methionine adenosyltransferase 1a (MAT1A) as one of the significantly upregulated genes following drug treatment. Survey of patient tumor sections confirmed elevated levels of MAT1A in individuals who received chemotherapy. Overexpression of MAT1A in 5637 bladder cancer cells increased tolerance to gemcitabine and stalled cell proliferation rates, suggesting MAT1A upregulation as a potential mechanism by which bladder cancer cells persist in a quiescent state to evade chemotherapy.",
keywords = "bladder cancer, drug resistance, gemcitabine, methyltransferase",
author = "Martin, {Kelly A.} and Hum, {Nicholas R.} and Aimy Sebastian and Wei He and Salma Siddiqui and Ghosh, {Paramita M.} and Pan, {Chong Xian} and {de Vere White}, Ralph and Loots, {Gabriela G.}",
year = "2019",
month = "10",
day = "9",
doi = "10.3390/ijms20204983",
language = "English (US)",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "20",

}

TY - JOUR

T1 - Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice

AU - Martin, Kelly A.

AU - Hum, Nicholas R.

AU - Sebastian, Aimy

AU - He, Wei

AU - Siddiqui, Salma

AU - Ghosh, Paramita M.

AU - Pan, Chong Xian

AU - de Vere White, Ralph

AU - Loots, Gabriela G.

PY - 2019/10/9

Y1 - 2019/10/9

N2 - Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer. We have utilized a patient-derived bladder cancer xenograft (PDX) platform to characterize molecular mechanisms that contribute to relapse following drug treatment in advanced bladder cancer. Transcriptomic profiling of bladder cancer xenograft tumors by RNA-sequencing analysis, before and after relapse, following a 21-day cisplatin/gemcitabine drug treatment regimen identified methionine adenosyltransferase 1a (MAT1A) as one of the significantly upregulated genes following drug treatment. Survey of patient tumor sections confirmed elevated levels of MAT1A in individuals who received chemotherapy. Overexpression of MAT1A in 5637 bladder cancer cells increased tolerance to gemcitabine and stalled cell proliferation rates, suggesting MAT1A upregulation as a potential mechanism by which bladder cancer cells persist in a quiescent state to evade chemotherapy.

AB - Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer. We have utilized a patient-derived bladder cancer xenograft (PDX) platform to characterize molecular mechanisms that contribute to relapse following drug treatment in advanced bladder cancer. Transcriptomic profiling of bladder cancer xenograft tumors by RNA-sequencing analysis, before and after relapse, following a 21-day cisplatin/gemcitabine drug treatment regimen identified methionine adenosyltransferase 1a (MAT1A) as one of the significantly upregulated genes following drug treatment. Survey of patient tumor sections confirmed elevated levels of MAT1A in individuals who received chemotherapy. Overexpression of MAT1A in 5637 bladder cancer cells increased tolerance to gemcitabine and stalled cell proliferation rates, suggesting MAT1A upregulation as a potential mechanism by which bladder cancer cells persist in a quiescent state to evade chemotherapy.

KW - bladder cancer

KW - drug resistance

KW - gemcitabine

KW - methyltransferase

UR - http://www.scopus.com/inward/record.url?scp=85073112250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073112250&partnerID=8YFLogxK

U2 - 10.3390/ijms20204983

DO - 10.3390/ijms20204983

M3 - Article

C2 - 31600961

AN - SCOPUS:85073112250

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 20

ER -